Arcellx, Inc. (ACLX)

$55.3

+0.11

(+0.2%)

Market is closed - opens 8 PM, 06 Dec 2023

Performance

  • $53.73
    $55.79
    $55.30
    downward going graph

    2.84%

    Downside

    Day's Volatility :3.69%

    Upside

    0.88%

    downward going graph
  • $18.70
    $56.09
    $55.30
    downward going graph

    66.18%

    Downside

    52 Weeks Volatility :66.66%

    Upside

    1.41%

    downward going graph

Returns

PeriodArcellx, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
49.66%
0.3%
0.0%
6 Months
34.81%
1.7%
0.0%
1 Year
191.21%
-4.0%
-2.4%
3 Years
229.17%
17.2%
-6.5%

Highlights

Market Capitalization
2.7B
Book Value
$5.47
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.65
Wall Street Target Price
60.09
Profit Margin
-274.59%
Operating Margin TTM
-299.94%
Return On Assets TTM
-19.03%
Return On Equity TTM
-51.56%
Revenue TTM
47.2M
Revenue Per Share TTM
1.01
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-143.1M
Diluted Eps TTM
-2.65
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.51
EPS Estimate Next Year
-2.22
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.68

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Arcellx, Inc.(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
16
16
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 8.66%

Current $55.30
Target $60.09

Technicals Summary

Sell

Neutral

Buy

Arcellx, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arcellx, Inc.
Arcellx, Inc.
22.08%
34.81%
191.21%
229.17%
229.17%
Moderna, Inc.
Moderna, Inc.
8.62%
-38.31%
-54.89%
-50.93%
320.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.38%
9.73%
9.82%
65.7%
115.07%
Novo Nordisk A/s
Novo Nordisk A/s
-1.43%
23.95%
58.41%
192.13%
336.59%
Seagen, Inc.
Seagen, Inc.
0.74%
10.42%
83.05%
20.41%
247.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.19%
7.19%
13.58%
55.97%
97.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arcellx, Inc.
Arcellx, Inc.
NA
NA
NA
-2.51
-0.52
-0.19
0.0
5.47
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arcellx, Inc.
Arcellx, Inc.
Buy
$2.7B
229.17%
NA
-274.59%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
320.86%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
115.07%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
336.59%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
247.89%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
97.18%
26.38
35.94%

Institutional Holdings

  • FMR Inc

    9.32%
  • Perceptive Advisors LLC

    8.15%
  • SR ONE CAPITAL MANAGEMENT, LP

    8.11%
  • NEA Management Company, LLC

    7.69%
  • Paradigm Biocapital Advisors LP

    6.07%
  • Suvretta Capital Management, LLC

    5.90%

Corporate Announcements

  • Arcellx, Inc. Earnings

    Arcellx, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.

Organization
Arcellx, Inc.
Employees
98
CEO
Mr. Rami Elghandour
Industry
Healthcare

FAQs